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Abstract
Modern strategies of STEMI/NSTEMI management, that include revascularization by coronary stenting, bypass
grafting, nowadays are used in 30-40% of urgent patients of such category. The prevalent part of patients is
treated by administration of the optimal drug therapy.
The objective of the research was to study the influence of adenosine-5-triphosphogluconate-magnesium
trisodium salt and levocarnitine on the clinical course of STEMI/NSTEMI.
Materials and methods. 100 patients with STEMI/NSTEMI were included into the research. Depending on
the therapy scheme, patients were divided into three groups and the control one. Determination of the key
parameters was performed initially after hospitalization and at the day of patient discharge.
Results. Promising results were shown while slowing the myocardial fibrosing. Limiting of the infarcted and
‘stunned‘ myocardium area resulted in ejection fraction increase, increase of the myocardial reserve, measured
by echocardiographic indexes.
Conclusions. Decreasing of myocardial fibrosing can be potentiated by the pharmacological postconditioning
as well as limiting of the necrotic myocardium area and increase of viable myocardium area. Pharmacological
postconditioning is effective and save, that can be proved by the absence of any serious complications.
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Problem statement and analysis of
the latest research
Modern strategies of STEMI/NSTEMI management,
that include revascularization by coronary stenting,
bypass grafting, nowadays are used in 30-40% of
urgent patients of such category. The prevalent
part of patients is treated by administration of the
optimal drug therapy. The coronary blood flow
restoration itself paradoxically leads to myocardial
injury and enlargement of the lesion zone up to
50% – so called reperfusion injury phenomenon,
that is realized through the endotoxicity of reactive
oxygen species, endothelial cells and macrophage
activation [1, 2, 3].
One of the possible ways of potentiating of the
standard STEMI/NSTEMI treatment scheme can be
recently discovered mechanism of preconditioning
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and postconditioning. It is proved that these pro-
cesses are aimed on the adaptation of myocardium
to ischemia and protection of myocardium from
metabolic damages because of the lasting cycle of
ischemia-reperfusion [4]. All known mechanisms
of myocardium conditioning converge to the pre-
vention of opening of the mitochondrial permeabil-
ity transition pore (mPTP), which is crucial and
leads to imminent cell death by apoptosis [4]. Ex-
tracellular adenosine acts as cytoprotective modu-
lator in physiological and pathological conditions
in response to organic or cellular stress, including
myocardial ischemia [5]. Nowadays, the influence
of adenosine is actively studied in clinical practice
(AMISTAD and AMISTAD-II clinical trials), so
as levocarnitine, that is endogenously synthetized
aminoacid and plays significant role as a cofactor in
fatty acids metabolism that results in ATP synthesis
[6, 7, 8].
The objective of the research was to study the in-
fluence of adenosine-5-triphosphogluconate-magne-
sium trisodium salt and levocarnitine on the clinical
course of STEMI/NSTEMI.
1. Materials and Methods
100 patients with STEMI/NSTEMI were included
in the research. 25 patients, which formed the con-
trol group, received standard therapy. The main
group of patients was divided into three subgroups
depending on the addition to the standard scheme:
1st subgroup (25 patients) received 30 mg of adenosine-
5-triphosphogluconate-magnesium trisodium salt
(domestic production drug ‘Advocard‘) 3 times per
day orally in addition to the standard therapy; 2nd
subgroup (25 patients) received 20 mg of levocarni-
tine (domestic production drug ’Tivor-L’ - levocar-
nitine mixture with l-arginine) in 1 infusion per day,
for 8-12 infusions per course as addition to the stan-
dard scheme; 3rd subgroup (25 patients) received
both of drugs in the same doses as the addition
to the standard scheme. Average age of included
patients was 63.6±0.80 years. 64% of patients
were men and 36% - women. All patients under-
went through standard clinical examinations (clini-
cal monitoring of STEMI/NSTEMI signs – dynam-
ics and changes of the pain syndrome, signs of pe-
ripheral hypoperfusion), ECG in 12 standard leads
(auxiliary lead systems where used on demand),
transthoracic echocardiography with detailed visu-
alization of segmental myocardial contraction (in-
cluding calculation of special indexes: index of
contractile function of myocardium – ICF; index of
remaining myocardial reserve – IRMR). ICF was
calculated by dividing stroke volume (SV) to end-
systolic volume (ESV). IRMR was calculated with
the help of I. Sledzevska’s (2012) method as the
end-systolic volume divided to the end-diastolic
volume (ESV/EDV; normally 0.38±0.01 units). In
case of ICF lowering to < 25-10% after the treat-
ment, the scheme was considered ineffective. In
case of IRMR was < 0.45, sufficient myocardial
reserve was observed; 0.45-0.55 meant restrictions
of the myocardial reserve; >0.56 meant serious
restrictions of myocardial reserve. Index of my-
ocardial mass of the left ventricle (IMMLV) was
used to characterize the structural changes in my-
ocardium. Also, the laboratory marker of cardiac
fibrosis (serum fibronectin) was studied. Statistical
analysis included data processing using methods
of parametrical and non-parametrical statistics, Stu-
dent’s t-criterium.
2. Results and Discussion
Results of the clinical monitoring after treatment
course showed (see Table 2), that patients of the
1st subgroup had slightly increased ejection frac-
tion (EF): from 48.43±0.609% to 51.27±0.785%
(p<0.05), 3rd subgroup showed better dynamics of
the EF: from 47.46% to 52.35% (p<0.05), while
control group did not show credible results: from
48.05% to 48.65% (p>0.05). ICF in the 1st sub-
group increased from 0.94±0.02 units to 1.06±0.03
units. Even better results were observed in the 3rd
group: from 0.90 units to 1.09 units (p<0.05). On
the contrary, the control group did not show credi-
ble results. IRMR showed tendency to decrease in
1st and 3rd subgroups: from 0.51 to 0.48 and from
0.53 to 0.48 units correspondingly (p<0.05) that
mean more effective involvement of the remain-
ing myocardial reserves. 2nd subgroup and con-
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Table 1. Dynamics of the main indexes before and after the treatment course.
Index Control group Main group
1st subgroup 2nd subgroup 3rd subgroup
Before After Before After Before After Before After
LVEF
48.05 48.65 48.43 51.27 51.25 53.56 47.46 52.35
[44.15-
50.28]
[46.77-
50.60];
±0.609 ±0.785; ±1.143 ±1.214; [45.27-
49.65]
[49.53-
55.72];
+1.2% +5.8%* +4.5% +10.3%*
ICF
0.92 0.94 0.94 1.06 0.98 1.08 0.90 1.09
[0.79-
1.01]
[0.87-
1.02];
±0.023 ±0.034; [0.90-
1.17]
[0.97-
1.36];
[0.83-
0.99]
[0.98-
1.26];
+2.1% +12.7%* +10.2% +21.1%*
IRMR
0.51 0.51 0.51 0.48 0.50 0.48 0.53 0.48
[0.49-
0.55]
[0.49-
0.53];
±0.006 ±0.008; [0.45-
0.52]
[0.42-
0.50];
[0.50-
0.55]
[0.44-
0.50];
0% -5.9%* -4% -9.5%*
IMMLV
151.21 129.84 200.63 158.13 162.65 168.72 142.93 137.78
[137.63-
167.79]
[118.25-
167.47];
±6.149 ±5.042; ±7.477 ±6.697; [129.39-
155.41]
[128.73-
154.31];
-14.2%* -21.2%* +3.7% -3.7%
Fibronectin
2.24 2.43 1.89 1.90 1.76 1.66 1.72 1.39
±0.131 ±0.124; [1.76-
2.16]
[1.78-
2.20];
±0.095 ±0.081; [1.47-
2.14]
[1.12-
1.74];
+8.4% +0.5% -5.7% -19.2%*
Note: * - p<0.05
trol group did not show credible results. IMMLV
credibly decreased in 1st subgroup of the main
group and in control group: from 200.63 to 158.13
g/kg/1.732 and from 151.21 to 129.84 13 g/kg/1.732
correspondingly (p<0.05) what proved the regres-
sion of postinfarction hypertrophy and remodeling
of left ventricle. Cardiac fibrosis credibly slowed
by 19, 2% in 3rd group (p<0.05) evaluated by the
serum fibronectin level. In the control group this
exponent grew up in 24 patients out of 25. The sum-
mary of all results indicates on the reducing of the
infarction size at the expense of restriction of the
‘scar‘ zone and increase of the viable myocardium
area.
3. Conclusions
Adenosine-5-triphosphogluconate-magnesium tri-
sodium salt is an effective way to increase the my-
ocardial contractility, correct excessive fibrosis, de-
crease the size of the myocardial infarction at the
expense of limitation of the ‘scar‘ zone, increase
of the viable myocardium area. Levocarnitine was
not as effective in case of solitary addition to the
treatment scheme. Treatment effectiveness essen-
tially increases in case of two drugs addition to the
therapy scheme. Cardiac fibrosis in postinfarction
period can be slowed down by combined usage of
both researched drugs. Application of both drugs
did not cause any serious side effect, so it is safe
and well tolerated.
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4. Prospects of Further
Researches
A comprehensive research of myocardial postcon-
ditioning can be performed to identify to effect of
postconditioning in patients that underwent percu-
taneous coronary intervention (PCI) of coronary
artery bypass grafting (CABG) with more severe
myocardial reperfusion injury.
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